Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

Koji Okabayashi, Tomonobu Fujita, Junichiro Miyazaki, Tsutomu Okada, Takashi Iwata, Nobumaru Hirao, Shinobu Noji, Nobuo Tsukamoto, Naoki Goshima, Hirotoshi Hasegawa, Hiroya Takeuchi, Masakazu Ueda, Yuukou Kitagawa, Yutaka Kawakami

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Esophageal squamous cell cancer (ESCC) is one of the most common lethal tumors in the world, and development of new diagnostic and therapeutic methods is needed. In this study, cancer-testis antigen, BORIS, was isolated by functional cDNA expression cloning using screening technique with serum IgG Abs from ESCC patients. BORIS was previously reported to show cancer-testis antigen like expression, but its immunogenicity has remained unclear in cancer patients. BORIS was considered to be an immunogenic antigen capable of inducing IgG Abs in patients with various cancers, including four of 11 ESCC patients. Immunohistochemical study showed that the BORIS protein was expressed in 28 of 50 (56%) ESCC tissues. The BORIS expression was significantly associated with lymph node metastasis in ESCC patients with pT1 disease (P = 0.036). Furthermore, the patients with BORIS-positive tumors had a poor overall survival (5-year survival rate: BORIS-negative 70.0% vs BORIS-positive 29.9%, log-rank P = 0.028) in Kaplan-Meier survival analysis and log-rank test. Multivariate Cox proportional hazard model demonstrated that BORIS expression was an independent poor prognostic factor (hazard ratio = 4.158 [95% confidence interval 1.494-11.57], P = 0.006). Downregulation of BORIS with specific siRNAs resulted in decreased cell proliferation and invasion ability of ESCC cell lines. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS-specific immunotherapy and molecular target therapy.

Original languageEnglish
Pages (from-to)1617-1624
Number of pages8
JournalCancer Science
Volume103
Issue number9
DOIs
Publication statusPublished - 2012 Sep

Fingerprint

Squamous Cell Neoplasms
Testicular Neoplasms
Esophageal Neoplasms
Antigens
Neoplasms
Immunoglobulin G
Kaplan-Meier Estimate
Survival Analysis
Proportional Hazards Models
Immunotherapy
Organism Cloning
Therapeutics
Down-Regulation
Survival Rate
Complementary DNA
Biomarkers
Lymph Nodes
Cell Proliferation
Confidence Intervals
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. / Okabayashi, Koji; Fujita, Tomonobu; Miyazaki, Junichiro; Okada, Tsutomu; Iwata, Takashi; Hirao, Nobumaru; Noji, Shinobu; Tsukamoto, Nobuo; Goshima, Naoki; Hasegawa, Hirotoshi; Takeuchi, Hiroya; Ueda, Masakazu; Kitagawa, Yuukou; Kawakami, Yutaka.

In: Cancer Science, Vol. 103, No. 9, 09.2012, p. 1617-1624.

Research output: Contribution to journalArticle

Okabayashi, K, Fujita, T, Miyazaki, J, Okada, T, Iwata, T, Hirao, N, Noji, S, Tsukamoto, N, Goshima, N, Hasegawa, H, Takeuchi, H, Ueda, M, Kitagawa, Y & Kawakami, Y 2012, 'Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer', Cancer Science, vol. 103, no. 9, pp. 1617-1624. https://doi.org/10.1111/j.1349-7006.2012.02355.x
Okabayashi, Koji ; Fujita, Tomonobu ; Miyazaki, Junichiro ; Okada, Tsutomu ; Iwata, Takashi ; Hirao, Nobumaru ; Noji, Shinobu ; Tsukamoto, Nobuo ; Goshima, Naoki ; Hasegawa, Hirotoshi ; Takeuchi, Hiroya ; Ueda, Masakazu ; Kitagawa, Yuukou ; Kawakami, Yutaka. / Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. In: Cancer Science. 2012 ; Vol. 103, No. 9. pp. 1617-1624.
@article{df5a9fb844fb4b358e0a1be89308c7ca,
title = "Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer",
abstract = "Esophageal squamous cell cancer (ESCC) is one of the most common lethal tumors in the world, and development of new diagnostic and therapeutic methods is needed. In this study, cancer-testis antigen, BORIS, was isolated by functional cDNA expression cloning using screening technique with serum IgG Abs from ESCC patients. BORIS was previously reported to show cancer-testis antigen like expression, but its immunogenicity has remained unclear in cancer patients. BORIS was considered to be an immunogenic antigen capable of inducing IgG Abs in patients with various cancers, including four of 11 ESCC patients. Immunohistochemical study showed that the BORIS protein was expressed in 28 of 50 (56{\%}) ESCC tissues. The BORIS expression was significantly associated with lymph node metastasis in ESCC patients with pT1 disease (P = 0.036). Furthermore, the patients with BORIS-positive tumors had a poor overall survival (5-year survival rate: BORIS-negative 70.0{\%} vs BORIS-positive 29.9{\%}, log-rank P = 0.028) in Kaplan-Meier survival analysis and log-rank test. Multivariate Cox proportional hazard model demonstrated that BORIS expression was an independent poor prognostic factor (hazard ratio = 4.158 [95{\%} confidence interval 1.494-11.57], P = 0.006). Downregulation of BORIS with specific siRNAs resulted in decreased cell proliferation and invasion ability of ESCC cell lines. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS-specific immunotherapy and molecular target therapy.",
author = "Koji Okabayashi and Tomonobu Fujita and Junichiro Miyazaki and Tsutomu Okada and Takashi Iwata and Nobumaru Hirao and Shinobu Noji and Nobuo Tsukamoto and Naoki Goshima and Hirotoshi Hasegawa and Hiroya Takeuchi and Masakazu Ueda and Yuukou Kitagawa and Yutaka Kawakami",
year = "2012",
month = "9",
doi = "10.1111/j.1349-7006.2012.02355.x",
language = "English",
volume = "103",
pages = "1617--1624",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer

AU - Okabayashi, Koji

AU - Fujita, Tomonobu

AU - Miyazaki, Junichiro

AU - Okada, Tsutomu

AU - Iwata, Takashi

AU - Hirao, Nobumaru

AU - Noji, Shinobu

AU - Tsukamoto, Nobuo

AU - Goshima, Naoki

AU - Hasegawa, Hirotoshi

AU - Takeuchi, Hiroya

AU - Ueda, Masakazu

AU - Kitagawa, Yuukou

AU - Kawakami, Yutaka

PY - 2012/9

Y1 - 2012/9

N2 - Esophageal squamous cell cancer (ESCC) is one of the most common lethal tumors in the world, and development of new diagnostic and therapeutic methods is needed. In this study, cancer-testis antigen, BORIS, was isolated by functional cDNA expression cloning using screening technique with serum IgG Abs from ESCC patients. BORIS was previously reported to show cancer-testis antigen like expression, but its immunogenicity has remained unclear in cancer patients. BORIS was considered to be an immunogenic antigen capable of inducing IgG Abs in patients with various cancers, including four of 11 ESCC patients. Immunohistochemical study showed that the BORIS protein was expressed in 28 of 50 (56%) ESCC tissues. The BORIS expression was significantly associated with lymph node metastasis in ESCC patients with pT1 disease (P = 0.036). Furthermore, the patients with BORIS-positive tumors had a poor overall survival (5-year survival rate: BORIS-negative 70.0% vs BORIS-positive 29.9%, log-rank P = 0.028) in Kaplan-Meier survival analysis and log-rank test. Multivariate Cox proportional hazard model demonstrated that BORIS expression was an independent poor prognostic factor (hazard ratio = 4.158 [95% confidence interval 1.494-11.57], P = 0.006). Downregulation of BORIS with specific siRNAs resulted in decreased cell proliferation and invasion ability of ESCC cell lines. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS-specific immunotherapy and molecular target therapy.

AB - Esophageal squamous cell cancer (ESCC) is one of the most common lethal tumors in the world, and development of new diagnostic and therapeutic methods is needed. In this study, cancer-testis antigen, BORIS, was isolated by functional cDNA expression cloning using screening technique with serum IgG Abs from ESCC patients. BORIS was previously reported to show cancer-testis antigen like expression, but its immunogenicity has remained unclear in cancer patients. BORIS was considered to be an immunogenic antigen capable of inducing IgG Abs in patients with various cancers, including four of 11 ESCC patients. Immunohistochemical study showed that the BORIS protein was expressed in 28 of 50 (56%) ESCC tissues. The BORIS expression was significantly associated with lymph node metastasis in ESCC patients with pT1 disease (P = 0.036). Furthermore, the patients with BORIS-positive tumors had a poor overall survival (5-year survival rate: BORIS-negative 70.0% vs BORIS-positive 29.9%, log-rank P = 0.028) in Kaplan-Meier survival analysis and log-rank test. Multivariate Cox proportional hazard model demonstrated that BORIS expression was an independent poor prognostic factor (hazard ratio = 4.158 [95% confidence interval 1.494-11.57], P = 0.006). Downregulation of BORIS with specific siRNAs resulted in decreased cell proliferation and invasion ability of ESCC cell lines. BORIS may be a useful biomarker for prognostic diagnosis of ESCC patients and a potential target for treatment including by BORIS-specific immunotherapy and molecular target therapy.

UR - http://www.scopus.com/inward/record.url?scp=84865778255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865778255&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2012.02355.x

DO - 10.1111/j.1349-7006.2012.02355.x

M3 - Article

C2 - 22676270

AN - SCOPUS:84865778255

VL - 103

SP - 1617

EP - 1624

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -